Advaxis Immunotherapeutic ADXS11-001 Phase 1 Survival Data Extended

2 of 15 Treated Patients Alive After 3.5 And 3.1 Years, Respectively

NORTH BRUNSWICK, N.J., Ongoing follow up of the surviving patients from the phase I study of ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has shown that two (2) of fifteen (15) treated patients or 13.3% are still alive 1,248 and 1,128 days after receiving their initial dose.

This result of 13.3% of treated patients alive at over three (3) years, post dosing, exceeds the-established historical finding that the one-year survival for these patients is approximately 5% irrespective of the treatment regimen administered. The one-year survival in the Advaxis trial was 53%. Similarly, once progression begins following a failure of prior cytotoxic treatment the median survival for these patients is 180 days as compared with 347 days in the Advaxis study.

More information on this clinical trial can be found in the published results of this trial (Vaccine 27 2009 3975–3983).

About The Phase I Trial

This phase I trial was conducted in women with advanced cervix cancer who had progressed following cytotoxic therapy. In most cases, these women had been treated with multiple therapeutic modalities including surgery, radiation and chemotherapy. It is accepted that once these patients fail cytotoxic therapy there is little that can be offered to cure their disease or extend life.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) immunotherapeutics that deliver engineered tumor antigens, which stimulate multiple, simultaneous, immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. The Company’s technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company's portals: advaxis.com |Facebooktwitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

 

Contact:

Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
Fax: 732-545-1084
cmir@advaxis.com